Hyqvia market forecast points to faster growth in Europe

The Business Research Company says the global Hyqvia market is set for strong growth as autoimmune disease cases rise, healthcare spending increases and more patients shift to home-based immunoglobulin treatment. North America led the market in 2025, while Europe is expected to grow fastest through the forecast period.

Why it matters: - Hyqvia demand is tied to broader growth in immunoglobulin therapy for primary immunodeficiency and autoimmune disease care. - The market outlook reflects a shift toward treatments that are less frequent, more convenient and easier to deliver at home. - Faster growth in Europe could reshape where providers, pharmacies and specialty care networks focus investment.

What happened: - The Business Research Company published a new Hyqvia market analysis on Nov. 4, 2026. - The report says the Hyqvia market is gaining attention because of advances in immunoglobulin therapies and a stronger focus on patient quality of life. - The company says Hyqvia is designed for adults and children with primary immunodeficiency. - Hyqvia combines human immune globulin (IgG) with recombinant human hyaluronidase (rHuPH20). - The therapy is given subcutaneously once every three to four weeks. - The report says Hyqvia can allow larger, less frequent infusions at a single site. - The product is also described as supportive for patients with low IgG levels caused by PI.

The details: - Historical growth is linked to limitations of intravenous immunoglobulin therapy, infection risk in PI patients, early adoption of subcutaneous immunoglobulin and rising demand for better quality of life. - Expansion of immunology specialty care also supported the market in the past. - Forecast growth is expected to come from more PI diagnoses, expanded home healthcare services, more pediatric PI management, preference for extended dosing intervals and growth in specialty pharmacy distribution. - The report highlights trends toward less frequent immunoglobulin infusions and broader use of subcutaneous immunoglobulin. - It also points to wider acceptance of home-based infusion treatment and stronger demand for combination immunotherapy products. - Common side effects may include injection site reactions, headaches and flu-like symptoms. - The report identifies rising autoimmune disease prevalence as a major driver. - The NIHR Imperial Biomedical Research Centre analyzed health records from 22 million people in May 2023 and found about 10% of the population had one or more of 19 common autoimmune diseases. - The same analysis found higher autoimmune disease prevalence in women, at 13%, than in men, at 7%. - The report also cites rising healthcare investment as a market catalyst. - The American Medical Association reported in April 2025 that US healthcare spending rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person. - The market report says those investments help support development and regulatory approvals for Hyqvia in immunodeficiency and chronic inflammatory demyelinating polyneuropathy, or CIDP. - North America held the largest share of the Hyqvia market in 2025. - Europe is expected to post the fastest growth during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 market reports include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics and future trend analysis. - The report offers a free sample and a full market report online: More information and the full report.

Between the lines: - The report frames Hyqvia as part of a broader move away from frequent clinic-based infusion models. - Growth in home healthcare and specialty pharmacy distribution suggests more treatment may move closer to patients. - The Europe growth outlook likely reflects both diagnosis trends and broader adoption of advanced therapies, not just product-specific demand. - The report’s emphasis on market intelligence tools signals a sales-oriented product as well as a market forecast.

What's next: - The report expects diagnosis rates, home infusion use and specialty pharmacy channels to keep expanding. - Europe will be the region to watch if the forecast growth pattern holds. - Continued healthcare spending and autoimmune disease detection could further support demand for immunoglobulin-based therapies. - More information is available through the company’s report links and contact details.